Latest Period
Q2 2026
Security Snapshot
Kymera Therapeutics, Inc. - COMMON STOCK (KYMR) Institutional Ownership
CUSIP: 501575104
13F Institutional Holders and Ownership History from Q3 2020 to Q2 2026
Institutions Reporting
273
Shares (Excl. Options)
96,943,096
Price
$114.67
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / COMMON STOCK
- Symbol
- KYMR on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 96,943,096
- Total 13F value
- $11,083,791,021
- Portfolio coverage rank
- 0.01%
- Share change
- +616,619
- Value change
- +$93,828,289
- Number of holders
- 273
- Shares outstanding
- 82,701,686
- SEC-reported price per share
- $107.01
- Insider filing price
- $107.01
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- KYMR - Kymera Therapeutics, Inc. - COMMON STOCK is tracked under CUSIP 501575104.
- 273 institutions reported positions in Q2 2026.
- 8 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 255 to 273 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $8,013,617,804 to $11,083,791,021.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 273 institutions filings for Q2 2026.
Security key
501575104
Latest holder period
Q2 2026
13F holders
273
13D/G owners
8
CIK / CUSIP context first
Open Q2 2026 holders
KYMR full holder history
Kymera Therapeutics, Inc. SEC filings
Kymera Therapeutics, Inc. company facts
Kymera Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 501575104:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
8
Security
KYMR
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| FMR LLC | 14% | +28% | $1,034,158,808 | +$243,712,112 | 11,681,450 | +31% | FMR LLC | 31 Mar 2026 |
| BAKER BROS. ADVISORS LP | 11% | +14% | $551,236,913 | +$127,711,627 | 8,676,797 | +30% | Baker Bros. Advisors LP | 09 Dec 2025 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 8.6% | +21% | $785,202,888 | +$222,416,366 | 7,112,345 | +40% | T. Rowe Price Associates, Inc. | 30 Jun 2026 |
| T. Rowe Price Investment Management, Inc. | 6.7% | $483,396,552 | 5,460,257 | T. Rowe Price Investment Management, Inc. | 31 Mar 2026 | |||
| BIOTECHNOLOGY VALUE FUND L P | 6.3% | -24% | $427,875,237 | -$133,224,759 | 5,237,151 | -24% | BVF PARTNERS L P/IL | 26 Jun 2026 |
| WELLINGTON MANAGEMENT GROUP LLP | 4.8% | -12% | $344,353,990 | -$46,322,968 | 3,889,687 | -12% | Wellington Management Group LLP | 31 Mar 2026 |
| BlackRock, Inc. | 5.4% | $165,983,856 | 3,803,227 | BlackRock, Inc. | 30 Jun 2025 | |||
| Atlas Venture Fund X, L.P. | 2.9% | $263,269,224 | 2,384,685 | Atlas Venture Fund X, L.P. | 30 Jun 2026 |
As of 30 Jun 2026, 273 institutional investors reported holding 96,943,096 shares of Kymera Therapeutics, Inc. - COMMON STOCK (KYMR). This represents 117% of the company’s total 82,701,686 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
98%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| FMR LLC | 15% | 12,349,256 | +5.5% | 0.06% | $1,416,089,213 |
| BAKER BROS. ADVISORS LP | 10% | 8,657,242 | 0% | 5% | $992,725,940 |
| Avoro Capital Advisors LLC | 9% | 7,474,747 | 0% | 7.7% | $857,129,238 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 8.6% | 7,112,980 | +17% | 0.08% | $815,646,000 |
| T. Rowe Price Investment Management, Inc. | 7.6% | 6,257,261 | +14% | 0.47% | $717,521,000 |
| BlackRock, Inc. | 6.7% | 5,538,210 | +9.4% | 0.01% | $635,066,535 |
| BVF INC/IL | 4.7% | 3,872,052 | -30% | 11% | $444,008,203 |
| WELLINGTON MANAGEMENT GROUP LLP | 4.4% | 3,675,028 | -5.5% | 0.07% | $421,415,461 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3.6% | 2,992,193 | +4.1% | 0.02% | $343,114,771 |
| Siren, L.L.C. | 3.5% | 2,935,830 | -7.9% | 6.8% | $336,651,626 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.5% | 2,932,378 | +1.8% | 0.01% | $336,255,785 |
| Atlas Venture Life Science Advisors, LLC | 3.4% | 2,847,541 | -38% | 37% | $326,527,526 |
| STATE STREET CORP | 3.3% | 2,737,226 | +15% | 0.01% | $313,877,705 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.2% | 1,816,331 | +10% | 0.01% | $208,316,264 |
| Capital Research Global Investors | 1.7% | 1,388,881 | -17% | 0.02% | $159,262,984 |
| GOLDMAN SACHS GROUP INC | 1.4% | 1,187,333 | +34% | 0.01% | $136,151,475 |
| UBS Group AG | 1.2% | 1,007,777 | -1.6% | 0.02% | $115,561,789 |
| ALLIANCEBERNSTEIN L.P. | 1.2% | 981,521 | +11% | 0.03% | $81,750,884 |
| Driehaus Capital Management LLC | 1.1% | 919,233 | -12% | 0.61% | $105,408,448 |
| Merck & Co., Inc. | 0.93% | 772,165 | 0% | 17% | $88,544,161 |
| NORGES BANK | 0.92% | 757,246 | 0.01% | $86,833,399 | |
| FEDERATED HERMES, INC. | 0.91% | 749,398 | +40% | 0.12% | $85,933,469 |
| DIMENSIONAL FUND ADVISORS LP | 0.9% | 745,152 | +26% | 0.02% | $85,421,500 |
| FRONTIER CAPITAL MANAGEMENT CO LLC | 0.9% | 740,866 | -2.5% | 0.79% | $84,955,104 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 0.89% | 736,866 | -16% | 0.02% | $84,496,423 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
24
Latest
Q2 2026
Rows shown
1-24 of 24
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 96,943,096 | $11,083,791,021 | +$93,828,289 | $114.67 | 273 |
| 2026 Q1 | 96,291,386 | $8,013,617,804 | +$522,635,907 | $83.29 | 255 |
| 2025 Q4 | 89,844,621 | $6,991,151,675 | +$715,972,868 | $77.81 | 254 |
| 2025 Q3 | 80,864,737 | $4,576,806,879 | +$137,276,130 | $56.60 | 207 |
| 2025 Q2 | 78,801,021 | $3,438,754,240 | +$270,821,262 | $43.64 | 208 |
| 2025 Q1 | 72,808,716 | $1,995,263,098 | +$5,348,226 | $27.37 | 171 |
| 2024 Q4 | 71,721,890 | $2,885,022,540 | +$14,409,751 | $40.23 | 177 |
| 2024 Q3 | 69,051,239 | $3,268,392,680 | +$183,360 | $47.33 | 174 |
| 2024 Q2 | 67,390,465 | $2,011,640,213 | +$5,551,590 | $29.85 | 153 |
| 2024 Q1 | 67,207,302 | $2,701,742,064 | +$296,832,171 | $40.20 | 161 |
| 2023 Q4 | 60,455,852 | $1,539,280,108 | +$89,020,891 | $25.46 | 134 |
| 2023 Q3 | 57,350,132 | $797,188,696 | -$18,249,775 | $13.90 | 120 |
| 2023 Q2 | 58,230,116 | $1,338,678,295 | +$29,100,921 | $22.99 | 124 |
| 2023 Q1 | 56,859,649 | $1,683,467,091 | +$23,131,891 | $29.63 | 123 |
| 2022 Q4 | 56,195,243 | $1,402,708,961 | +$98,529,765 | $24.96 | 116 |
| 2022 Q3 | 52,859,306 | $1,150,805,258 | +$29,150,428 | $21.77 | 119 |
| 2022 Q2 | 49,442,050 | $973,574,555 | +$16,502,218 | $19.69 | 99 |
| 2022 Q1 | 45,688,568 | $1,933,296,396 | +$62,437,636 | $42.32 | 124 |
| 2021 Q4 | 43,015,870 | $2,729,867,438 | +$128,644,677 | $63.49 | 123 |
| 2021 Q3 | 34,637,185 | $2,035,073,191 | +$491,859,746 | $58.74 | 115 |
| 2021 Q2 | 26,479,657 | $1,284,263,574 | +$188,105,374 | $48.50 | 109 |
| 2021 Q1 | 22,191,421 | $862,345,865 | +$92,686,286 | $38.86 | 94 |
| 2020 Q4 | 20,299,967 | $1,247,002,136 | +$53,009,741 | $62.00 | 74 |
| 2020 Q3 | 16,828,031 | $542,529,000 | +$542,529,000 | $32.31 | 51 |